TMEXPLORE
LIVE

Serial Number

79299814

Owner

HalioDx

Attorney

Stanley M. Schurgin

Filing Date

Oct 1, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TMEXPLORE Trademark

Serial Number: 79299814 • Registration: 6481164

TMEXPLORE is a trademark filed by HalioDx on October 1, 2020. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

HalioDx (6 trademarks)

163 Avenue de Luminy,
F-13288 Marseille Cédex 09 , FR

Entity Type: 34

VERACYTE (7 trademarks)

PARC SCIENTIFIQUE DE LUMINY

Entity Type: 34

Trademark Details

Filing Date

October 1, 2020

Registration Date

September 14, 2021

Published for Opposition

June 29, 2021

Goods & Services

Medical analysis services relating to the clinical diagnostic and ongoing evaluation, analysis and study of a cancer or tumor microenvironment; medical assistance; health services namely health assessment services; pharmaceutical compound evaluation services; therapeutic services in the field of oncology diagnosis; medical diagnostics, diagnostics in the field of medicine; genetic and/or tissue analysis services for medical purposes; medical testing services for diagnostic or treatment purposes; medical services for the detection, qualification, localization of proteins or cells on a section of biological tissue for the purposes of medical diagnosis

Research, development, technical design and scientific testing services in the field of oncology; research and development of new products for third parties in the pharmaceutical field; industrial analysis and research services in the field of oncology; biomarker analysis services for pharmaceutical research purposes; microbiological testing services for medical and scientific research; testing biomarkers for clinical trials; tests in laboratories namely testing of cancer related biomarkers; laboratory research services concerning pharmaceutical products; development of testing methods namely development of testing specifications and procedures for the characterization of tumors and tumor microenvironment; research, development, technical design, testing, analysis services and consultation services related thereto in the fields of immunology and oncology; Research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; research services in the fields of biomarker analysis, immune repertoire analysis, tissue and genome analysis; design and development of software in the field of biology

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Aug 21, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 10, 2022 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Mar 4, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Mar 4, 2022 XXCR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 12, 2022 ADCH
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 14, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 14, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 29, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 29, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 9, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 23, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 4, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 4, 2021 TROA
REFUSAL PROCESSED BY IB
Apr 5, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 18, 2021 RFCS
REFUSAL PROCESSED BY MPU
Mar 17, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 13, 2021 RFCR
NON-FINAL ACTION WRITTEN
Mar 12, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 26, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 18, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 14, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 11, 2020 REPR